2021
DOI: 10.3390/antiox10060979
|View full text |Cite
|
Sign up to set email alerts
|

Electron Donor–Acceptor Capacity of Selected Pharmaceuticals against COVID-19

Abstract: More than a year ago, the first case of infection by a new coronavirus was identified, which subsequently produced a pandemic causing human deaths throughout the world. Much research has been published on this virus, and discoveries indicate that oxidative stress contributes to the possibility of getting sick from the new SARS-CoV-2. It follows that free radical scavengers may be useful for the treatment of coronavirus 19 disease (COVID-19). This report investigates the antioxidant properties of nine antiviral… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 45 publications
0
6
0
Order By: Relevance
“…With these parameters, it is possible to determine the electron donor–acceptor MAP (DAM) (see Figure ). These chemical descriptors have been used successfully in many different chemical systems. , …”
Section: Methodsmentioning
confidence: 99%
“…With these parameters, it is possible to determine the electron donor–acceptor MAP (DAM) (see Figure ). These chemical descriptors have been used successfully in many different chemical systems. , …”
Section: Methodsmentioning
confidence: 99%
“…Molnupiravir is an electron acceptor but not a good one, which means it is not an effective oxidant. Therefore, it is side effect can be minimum from this viewpoint when be used against COVID-19 ( Martínez, 2021 ).…”
Section: The Effect Of Molnupiravir On Host Cellmentioning
confidence: 99%
“…There are still four clinical trials ongoing, according to www.clinicaltrials.gov (as at December 12, 2021). Moreover, it is not a potent agent for oxidational stress, which increases its safety [39]. However, there are still some concerns about mutagenesis in mam-malian cells [40,41].…”
Section: Molnupiravir Lagevrio®mentioning
confidence: 99%